Reverse Engineering Glioma Radiomics to Conventional Neuroimaging

Neurol Med Chir (Tokyo). 2021 Sep 15;61(9):505-514. doi: 10.2176/nmc.ra.2021-0133. Epub 2021 Aug 6.

Abstract

A novel radiological research field pursuing comprehensive quantitative image, namely "Radiomics," gained traction along with the advancement of computational technology and artificial intelligence. This novel concept for analyzing medical images brought extensive interest to the neuro-oncology and neuroradiology research community to build a diagnostic workflow to detect clinically relevant genetic alteration of gliomas noninvasively. Although quite a few promising results were published regarding MRI-based diagnosis of isocitrate dehydrogenase (IDH) mutation in gliomas, it has become clear that an ample amount of effort is still needed to render this technology clinically applicable. At the same time, many significant insights were discovered through this research project, some of which could be "reverse engineered" to improve conventional non-radiomic MR image acquisition. In this review article, the authors aim to discuss the recent advancements and encountering issues of radiomics, how we can apply the knowledge provided by radiomics to standard clinical images, and further expected technological advances in the realm of radiomics and glioma.

Keywords: T2-FLAIR mismatch; glioma; quantitative imaging; radiomics.

Publication types

  • Review

MeSH terms

  • Artificial Intelligence
  • Brain Neoplasms* / diagnostic imaging
  • Brain Neoplasms* / genetics
  • Glioma* / diagnostic imaging
  • Glioma* / genetics
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Magnetic Resonance Imaging
  • Mutation
  • Neuroimaging
  • Retrospective Studies

Substances

  • Isocitrate Dehydrogenase